SOUTHLAKE, Texas, Oct. 5, 2022 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biotechnology company developing breakthrough products for cardiorenal diseases, today announced that management will present a company overview and will conduct 1x1s with investors at the following conferences:
Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving and extending patients' lives by developing breakthrough products to prevent disease progression, improve outcomes and protect against organ damage in cardiorenal diseases. The Company has developed a robust portfolio of products that act by inducing organ preconditioning via activation of multiple cytoprotective pathways. Renibus' lead program, RBT-1, is an anti-inflammatory and antioxidant "pipeline-in-a-product" which is currently in Phase 2 development in cardiac surgery, and about to enter a Phase 3 registration study for its lead indication to reduce the risk of postoperative complications following cardiothoracic surgery. RBT-2 is an antioxidant and anti-fibrotic that has shown in preclinical models to reduce the risk of CKD progression. RBT-3, which is in clinical development, is targeted at reducing the risk of cisplatin induced nephrotoxicity.
For more information, please visit the Company's website at www.Renibus.com and engage with us on LinkedIn.
Investor and Media Contact:
Amy Conrad
Juniper Point
amy@juniper-point.com
858-914-1962
SOURCE Renibus Therapeutics
